Floatz Rating
B57/100
Confidence
Indicative
Sponsor
Magenta Therapeutics, Inc.
Modality
UNKNOWN
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03406962CT.gov MGTA-456 in Patients With Inherited Metabolic Disorders Undergoing Hematopoietic Stem Cell Transplantation (HSCT) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Inborn Errors Of Metabolism
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Mgta-456 (this asset) | Magenta Therapeutics, Inc. | P2 | B · 57 |
| Nexiguran Ziclumeran | Intellia Therapeutics | P3 | B |
| Thiotepa | University of California, San Francisco | P2 | CCC |
| Hydroxyurea | Paul Szabolcs | P2 | CCC |
| Busulfanum | Memorial Sloan Kettering Cancer Center | P2 | CCC |
| Cald Hr-D | Masonic Cancer Center, University of Minnesota | P2 | CCC |
| Alemtuzumab | Paul Szabolcs | P2 | CCC |
| Hpc, Cord Blood | Memorial Sloan Kettering Cancer Center | P2 | CCC |
| Cyclosporin A | Memorial Sloan Kettering Cancer Center | P2 | CCC |
+7 more in the Inborn Errors Of Metabolism cohort
Other indications for Mgta-456
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Lymphoblastic Leukemia | — | P2 | CCC · 53 |
| Acute Leukemia Of Ambiguous Lineage | — | P2 | CCC · 53 |
| Chronic Myeloid Leukemia | — | P2 | CCC · 53 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Mgta-456 in Inborn Errors Of Metabolism. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/mgta-456-inborn-errors-of-metabolism
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →